From CNBC: 2024-05-07 13:41:18

Wegovy, a new injectable weight-loss medication, is available at New City Halstead Pharmacy in Chicago. Amgen’s drug, MariTide, could challenge Novo Nordisk and Eli Lilly’s duopoly in the weight loss market due to its less frequent dosing and potential for longer-lasting weight loss. Other companies like Boehringer Ingelheim, Zealand Pharma, Novo Nordisk, and Eli Lilly are also developing new weight loss treatments. Amgen’s MariTide may have fewer side effects with longer-lasting weight loss and less frequent dosing compared to existing treatments like Wegovy and Zepbound. AstraZeneca, Boehringer Ingelheim, Pfizer, and other companies are in various stages of developing new weight loss medications. Novo Nordisk’s CagriSema and Eli Lilly’s retatrutide and orforglipron also show promise in helping patients lose weight. Boehringer Ingelheim and Zealand Pharma’s survodutide aims to target obesity and liver disease, with a potential launch date in 2027 or 2028. AstraZeneca’s daily obesity pill and experimental drug AZD6234 are also in development. Pfizer is awaiting new data on its once-daily obesity pill expected mid-year.



Read more at CNBC: Amgen could threaten Novo Nordisk, Eli Lilly weight loss drug dominance